Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-NKG2DL gamma delta CAR-T cell therapy - Cytomed Therapeutics

Next Previous
Drug Profile

Anti-NKG2DL gamma delta CAR-T cell therapy - Cytomed Therapeutics

Alternative Names: CTM-GDT therapy - Cytomed Therapeutics; CTM-N2D - Cytomed Therapeutics; Haplo/ allogeneic NKG2DL-targetting chimeric antigen receptor-grafted γδ T cell therapy - Cytomed Therapeutics; Haploidentical/ allogeneic natural killer group 2D ligand CAR-γδT cell therapy - Cytomed Therapeutics; NKG2DL-targetting chimeric antigen receptor-grafted gamma delta T cell therapy - Cytomed Therapeutics

Latest Information Update: 16 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CytoMed Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Solid tumours

Highest Development Phases

  • Phase I Haematological malignancies; Solid tumours

Most Recent Events

  • 28 Apr 2025 Cytomed Therapeutics plans a phase II trial in Cancer in India in the second half of 2025
  • 29 Jan 2024 CytoMed Therapeutics has patent protection for chimeric antigen receptor gamma delta T cell (“CAR-γδ T cell”) technology in Malaysia
  • 28 Oct 2023 No recent reports of development identified for preclinical development in Solid-tumours in Singapore (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top